T he treatment of atherosclerosis during the past 2 decades has been focused on reductions in atherogenic lipids, such as low-density lipoprotein cholesterol, and, more recently, has moved toward attempting to increase high-density lipoprotein cholesterol. However, another major component of atherosclerosis is inflammation. Although long recognized in the laboratory, clinical investigators 1 have more recently measured high-sensitivity C-reactive protein (hsCRP) in large clinical trials and linked higher levels with increased risk of mortality and cardiovascular events. This has led to intense interest in inflammation as a target for treatment, with the possibility that it could be the "next big thing" in managing atherosclerosis.
See accompanying article on page 2256
With this information as a backdrop, the model of vascular injury used by Sarov-Blat et al 2 allows initial testing of the effects of a novel antiinflammatory agent in patients with atherosclerosis. The paradigm of coronary stenting, leading to vascular injury and resulting in an inflammatory response that signals neointimal proliferation, and subsequent in-stent restenosis share many similar features of the inflammatory cascade that propagates atherosclerosis. 3, 4 Such extracellular stimuli are relayed to coordinated cellular responses through intracellular phosphorylation cascades, such as the mitogenactivated protein kinase (MAPK) pathways. 5 So far, 4 classes of mammalian MAPK have been identified: extracellular signal-regulated kinases, c-jun N-terminal kinase or stressactivated protein kinase, extracellular signal-regulated kinase/big MAP kinase 1, and the p38 MAPKs. 6 In their study, Sarov-Blat et al turn their attention to the inhibition of p38 MAPK using a newly developed agent to attenuate the inflammatory stimulus generated by vascular injury. The p38 MAPK is a serine kinase that plays a fundamental role in inflammatory responses. 7 Various stressors activate the p38 MAPK pathway, including inflammatory cytokines, osmotic shock, endotoxin, cigarette smoke, and various growth factors. There are 4 isoforms (␣, ␤, ␦, and ␥) of p38 MAPK. There is variable cellular expression of ␦ and ␥, whereas the ␣ and ␤ isoforms are more universally expressed. The compound studied, SB-681323, is an inhibitor of both the p38␣ and p38␤ MAPK. Knockout mouse models of p38␤ suggest that p38␣ is the predominant form involved in the inflammatory response. 8 The p38 MAPK pathway has been implicated in other inflammatory diseases, including rheumatoid arthritis, Alzheimer disease, and inflammatory bowel disease. 9 -11 This pathway plays a central role in the activation and production of key proinflammatory cytokines, including interleukin 1␤, tumor necrosis factor ␣, and interleukin 6. 6 In fact, p38 MAPK was initially discovered during a pharmacological screen for molecules that modulate tumor necrosis factor ␣ production. 12 Furthermore, p38 MAPK induces inflammatory enzymes, such as cyclooxygenase-2 and inducible NO synthase. 13, 14 Bone resorption through receptor activator for nuclear factor ␤ ligand and the expression of certain matrix metalloproteinases are also activated by the p38 pathway. 15, 16 The p38 MAPK pathway, such as all MAP kinases, is regulated by MAPK kinases (MKKs). Specifically, MKK3 and MKK6 regulate p38␣ and p38␤ MAPKs; although MKK4 predominantly regulates c-jun N-terminal kinase, it also can assist in p38␣ MAPK activation. 7, 17 An MKKindependent activating pathway appears to occur through transforming growth factor-␤-activated protein kinase 1 binding protein. 18 Data suggest that activation of these different activators may occur during different physiological states.
In the current study by Sarov-Blat et al, 2 the researchers randomized patients with a planned single-vessel percutaneous coronary intervention with coronary artery stenting to a p38 MAPK inhibitor or placebo. The potent inflammatory reaction elicited by coronary stenting provides sufficient p38 MAPK stimulation, which would presumably further propagate inflammatory cytokines and enzymes, thereby leading to neointimal hyperplasia and, ultimately, in-stent restenosis. 19 The degree of inflammation was followed by hsCRP. Various inflammatory biomarkers have been studied to predict cardiovascular events, but hsCRP has the most robust data as an independent marker of cardiovascular disease. Furthermore, in the setting of coronary stent-mediated injury, hsCRP levels increase with implantation and correlate with the risk of restenosis, further implicating an inflammatory response as a marker of cardiovascular outcomes in a clinical model of endothelial injury. 20, 21 Sarov-Blat et al 2 demonstrated that, with p38 MAPK inhibition, there was significant attenuation of hsCRP values starting from the day of stent placement in this phase 2 trial. Two days after stent implantation, when hsCRP levels were at their peak, p38 MAPK inhibition resulted in a 29% relative reduction in hsCRP. Impressively, hsCRP values returned to baseline 1 week after coronary intervention with the p38 MAPK inhibitor; however, nearly 1 month was needed without the p38 MAPK inhibitor. This trend of hsCRP suppression was noted with both bare metal and drug-eluting stents.
These results are exciting for the emerging interest in antiinflammatory therapy for atherosclerosis. The researchers have shown that an inhibitor of p38 MAPK suppresses an inflammatory response of vascular injury. This has potential applications to in-stent restenosis prevention and, more importantly, to potential medical treatment of coronary atherosclerosis by inhibiting the deleterious effects of local inflammation. An important limitation of this trial is that evidence suggests that inhibition of p38 MAPK may directly inhibit hepatic production of CRP. 21 This may limit the role of hsCRP as a marker of inflammation derived from the vasculature in studies of p38 MAPK inhibitors; however, the short-term phase reactant, serum amyloid A, does not appear to be directly affected and may be a more reliable marker of inflammation in this setting. 21 Although it does not have the abundance of data of hsCRP, serum amyloid A appears to correlate with cardiovascular disease progression and outcomes. [22] [23] [24] The measurement of inflammatory cytokines is difficult given their significant variability, but a trend of interleukin 6 suppression with SH-681323 in the current study by Sarov-Blat et al 2 suggests an antiinflammatory effect that could not be explained by decreasing hepatic synthesis of CRP. In addition, a reduction in tumor necrosis factor ␣ was seen when SB-681323 was given to patients with chronic obstructive pulmonary disease. 25 A key consequence of the reduced inflammation is the apparent benefit on reduction of actual cardiovascular events. Markers that have been used are post-percutaneous coronary intervention markers of myocardial necrosis. Although a nonsignificantly lower percentage of patients had troponin elevations (40% versus 53%), the actual mean values were slightly higher troponin I values the day after stent deployment; however, none of these differences were significant given the small sample size of this study. The rates of cardiovascular end points actually favored SB-681323: coronary revascularization was significantly reduced. Although obviously not designed or powered to demonstrate differences in clinical end points, it is encouraging to see cardiovascular events be lower in the active treatment group.
An important result of this study is the safety profile of SB-681323. The lack of apparent infections is a key concern in the suppression of the inflammatory cascade. Wound healing is another concern, particularly in a patient with more extensive coronary disease requiring surgical revascularization.
Whether p38 MAPK inhibition can truly attenuate the incidence of in-stent restenosis, or even the progression of coronary atherosclerosis, will require further larger studies, but the data presented by Sarov-Blat et al 2 in this "proof-ofprinciple" study are promising. The development of antiinflammatory agents targeting distinct inflammatory path-ways represents a promising trend in the treatment of cardiovascular disease.
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